PARP1介导的PPARα多聚ADP核糖基化抑制非酒精性脂肪性肝病中的脂肪酸氧化
该研究在小鼠高脂饮食模型和NAFLD患者肝活检中分析PARP1活性,发现脂肪肝中PARP1被激活,其介导的PPARα多聚ADP核糖基化抑制PPARα信号及脂肪酸氧化;药物或遗传操作PARP1可改变高脂饮食诱导的肝脂肪变性和炎症。
要点
- 高脂饮食喂养小鼠脂肪肝及NAFLD患者肝活检中PARP1活性升高。
- PARP1介导PPARα多聚ADP核糖基化,抑制其招募至靶基因启动子及与SIRT1交互。
- 药物抑制PARP1可减轻小鼠脂肪肝的脂质蓄积和炎症。
核心结论
- PARP1在脂肪肝中被激活,通过抑制PPARα信号阻止脂肪酸氧化的最大激活。
- 药物抑制PARP1可能缓解PPARα抑制,因此对NAFLD具有治疗潜力。
研究设计与样本
- 研究分析高脂饮食小鼠肝脏及NAFLD患者样本中PARP1活性。
- 采用功能获得或缺失方法研究肝脏PARP1在NAFLD发病中的作用和机制。
主要发现
- 高脂饮食喂养小鼠脂肪肝中PARP1被激活。
- 药物或遗传操作PARP1足以改变高脂饮食诱导的肝脂肪变性和炎症。
- PARP1介导的PPARα多聚ADP核糖基化抑制PPARα招募至靶基因启动子及其与SIRT1的交互,导致脂肪酸诱导的脂肪酸氧化上调受抑制。
- 在人类肝细胞中PARP1是PPARα基因的转录抑制因子,其激活抑制配体(非诺贝特)诱导的PPARα反式激活及靶基因表达。
- NAFLD患者肝活检显示PARP活性和PPARα多聚ADP核糖基化水平显著增加。
临床怎么用
- 作者认为药物抑制PARP1可能缓解PPARα抑制,因此对NAFLD具有治疗潜力。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: PARP1 is a key mediator of cellular stress responses and critical in multiple physiological and pathophysiological processes of cells. However, whether it is involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) remains elusive. METHODS: We analysed PARP1 activity in the liver of mice on a high fat diet (HFD), and samples from NAFLD patients. Gain- or loss-of-function approaches were used to investigate the roles and mechanisms of hepatic PARP1 in the pathogenesis of NAFLD. RESULTS: PARP1 is activated in fatty liver of HFD-fed mice. Pharmacological or genetic manipulations of PARP1 are sufficient to alter the HFD-induced hepatic steatosis and inflammation. Mechanistically we identified peroxisome proliferator-activated receptor α (PPARα) as a substrate of PARP1-mediated poly(ADP-ribosyl)ation. This poly(ADP-ribosyl)ation of PPARα inhibits its recruitment to target gene promoters and its interaction with SIRT1, a key regulator of PPARα signaling, resulting in suppression of fatty acid oxidation upregulation induced by fatty acids. Moreover, we show that PARP1 is a transcriptional repressor of PPARα gene in human hepatocytes, and its activation suppresses the ligand (fenofibrate)-induced PPARα transactivation and target gene expression. Importantly we demonstrate that liver biopsies of NAFLD patients display robust increases in PARP activity and PPARα poly(ADP-ribosyl)ation levels. CONCLUSIONS: Our data indicate that PARP1 is activated in fatty liver, which prevents maximal activation of fatty acid oxidation by suppressing PPARα signaling. Pharmacological inhibition of PARP1 may alleviate PPARα suppression and therefore have therapeutic potential for NAFLD. LAY SUMMARY: PARP1 is activated in the non-alcoholic fatty liver of mice and patients. Inhibition of PARP1 activation alleviates lipid accumulation and inflammation in fatty liver of mice.
引用
- Huang K, Du M, Tan X, et al. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. J Hepatol. 2016. PMID: 27979751. doi:10.1016/j.jhep.2016.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。